CHC

Key Product Details

Product Description

CHC is a monocarboxylic acid transport (MCT) inhibitor. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration, and invasion in U251 cells. Enhances the effect of antitumor agent temozolomide (Cat No. 2706). Blocks lactate efflux from glioma cells and sensitizes cells to irradiation.

Product Specifications for CHC

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CHC

The following data is based on the product molecular weight 189.17.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	5.29 mL	26.43 mL	52.86 mL
5 mM	1.06 mL	5.29 mL	10.57 mL
10 mM	0.53 mL	2.64 mL	5.29 mL
50 mM	0.11 mL	0.53 mL	1.06 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 8 publications citing the usage of this product.

• Colen Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 2006 PMID: 17277695
• Fang The H⁺-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol.Pharmacol. 2006 PMID: 17000864
• Dimmer The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem.J. 2000 PMID: 10926847
• Miranda-Gonçalves Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro.Oncol. 2013 PMID: 23258846

Product Documents for CHC